Hauber H, Taha Rame, Bergeron Celine, Migounov Vladimir, Hamid Qutayba, Olivenstein Ron
Meakins-Christie Laboratories, McGill University, Montreal, Canada.
Can Respir J. 2006 Mar;13(2):73-8. doi: 10.1155/2006/648392.
Inhaled corticosteroids are powerful drugs that can suppress airway inflammation in asthmatic patients. Deposition of most of the inhaled corticosteroid occurs mainly in the central airways. However, a new hydrofluoroalkane formulation of beclomethasone dipropionate (HFA-BDP) is preferentially deposited in the distal airways. Inflammatory characteristics of induced sputum have been shown to differ in samples collected early after sputum induction compared with later.
To compare the effects of HFA-BDP and budesonide in a dry powder inhaler (DPI-BUD) on inflammatory cells and inflammatory cytokine expression in early and late induced sputa compared with placebo.
Seventeen patients with mild, intermittent bronchial asthma were randomly assigned to two treatment groups: eight patients received HFA-BDP and nine patients received DPI-BUD. Each patient was treated with one of the active treatments and placebo (for four weeks), with a two-week washout interval in between. Inflammatory cells and expression of interleukin (IL)-4 and IL-5 were measured in early and late induced sputa before and after active treatment, as well as before and after placebo treatment using immunocytochemistry and in situ hybridization.
Compared with placebo, eosinophils were significantly reduced in both early and late induced sputa after HFA-BDP treatment (P<0.05), whereas DPI-BUD had a significant effect only on early induced sputum. Both HFA-BDP and DPI-BUD decreased IL-4 expression in early and late induced sputa, but the effect was more prominent with HFA-BDP. IL-5 expression was reduced in both early and late induced sputa after HFA-BDP treatment. DPI-BUD significantly decreased IL-5 expression in early but not in late induced sputum. The number of lymphocytes was not altered by either treatment.
HFA-BDP reduced eosinophilic inflammation and T helper 2-type cytokine expression in both early and late induced sputa, whereas the effect of DPI-BUD on inflammation was predominantly demonstrated in early induced sputum.
吸入性糖皮质激素是能够抑制哮喘患者气道炎症的强效药物。大多数吸入性糖皮质激素主要沉积在中央气道。然而,一种新的二丙酸倍氯米松氢氟烷制剂(HFA-BDP)优先沉积在远端气道。已表明,诱导痰早期采集的样本与后期采集的样本相比,其炎症特征有所不同。
比较HFA-BDP和布地奈德干粉吸入剂(DPI-BUD)与安慰剂相比,对早期和晚期诱导痰中炎症细胞及炎症细胞因子表达的影响。
17例轻度间歇性支气管哮喘患者被随机分为两个治疗组:8例患者接受HFA-BDP治疗,9例患者接受DPI-BUD治疗。每位患者接受一种活性治疗和安慰剂治疗(为期4周),中间有2周的洗脱期。在活性治疗前后以及安慰剂治疗前后,使用免疫细胞化学和原位杂交技术检测早期和晚期诱导痰中的炎症细胞以及白细胞介素(IL)-4和IL-5的表达。
与安慰剂相比,HFA-BDP治疗后早期和晚期诱导痰中的嗜酸性粒细胞均显著减少(P<0.05),而DPI-BUD仅对早期诱导痰有显著作用。HFA-BDP和DPI-BUD均降低了早期和晚期诱导痰中IL-4的表达,但HFA-BDP的效果更显著。HFA-BDP治疗后早期和晚期诱导痰中IL-5的表达均降低。DPI-BUD显著降低了早期诱导痰中IL-5的表达,但对晚期诱导痰无此作用。两种治疗均未改变淋巴细胞数量。
HFA-BDP降低了早期和晚期诱导痰中的嗜酸性粒细胞炎症以及辅助性T细胞2型细胞因子的表达,而DPI-BUD对炎症的作用主要体现在早期诱导痰中。